Spero Therapeutics
SPRO
48 hedge funds and large institutions have $20.6M invested in Spero Therapeutics in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 15 increasing their positions, 7 reducing their positions, and 13 closing their positions.
114% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 7
0.05% more ownership
Funds ownership: 27.47% → 27.52% (+0.05%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
16% less capital invested
Capital invested by funds: $24.6M → $20.6M (-$3.98M)
20% less funds holding
Funds holding: 60 → 48 (-12)
77% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 13
79% less call options, than puts
Call options by funds: $30K | Put options by funds: $145K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$623K |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$544K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$184K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$136K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$135K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$639K |
| 2 |
OMC
Oasis Management Company
Grand Cayman,
Cayman Islands
|
-$498K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$380K |
| 4 |
VF
Virtu Financial
New York
|
-$59K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$54.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Corient Private Wealth
Miami,
Florida
| – | -$30.3K | -17,500 | Closed |
|
52
Prudential Financial
Newark,
New Jersey
| – | -$25.3K | -14,600 | Closed |
|
|
SPA
53
Sentinel Pension Advisors
Wakefield,
Massachusetts
| – | -$20.8K | -12,000 | Closed |
|
54
Stifel Financial
St. Louis,
Missouri
| – | -$18.6K | -10,766 | Closed |
|
|
CG
55
Colony Group
Boston,
Massachusetts
| – | -$17K | -10,000 | Closed |
|
56
Simplex Trading
Chicago,
Illinois
| – | -$15.4K | -9,206 | Closed |
|
|
BAM
57
Belpointe Asset Management
Reno,
Nevada
| – | -$7.89K | -4,560 | Closed |
|
58
BNP Paribas Financial Markets
Paris,
France
| – | -$1.16K | -668 | Closed |
|
|
APC
59
Aspire Private Capital
Cornelius,
North Carolina
| – | -$173 | -100 | Closed |
|
SPRO Hedge Fund Activity: Q1 2023 in Review
48 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Spero Therapeutics (SPRO) for Q1 2023, worth a combined $20.6M — down 16% from $24.6M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of SPRO and 3 opened new positions — a net loss of 10 holders — while 7 trimmed existing stakes and 15 added.
The largest buyer was Vanguard Group, adding an estimated $623K. The largest seller was Millennium Management, cutting an estimated $639K.
- 48 institutional investors held Spero Therapeutics (SPRO) as of Q1 2023, down from 60 in Q4 2022.
- Funds reported $20.6M of Spero Therapeutics stock for Q1 2023, down 16% quarter-over-quarter.
- 3 funds opened new Spero Therapeutics positions in Q1 2023 and 13 closed out, a net change of -10 holders.
- The largest Spero Therapeutics buyer in Q1 2023 was Vanguard Group, an estimated $623K added.
- The largest Spero Therapeutics seller in Q1 2023 was Millennium Management, an estimated $639K sold.
Based on aggregated 13F filings for Q1 2023.